Table 3 Baseline characteristics and mortality of patients who had septic shock according to norepinephrine- vs. vasopressin-treated infusion prior to and after matching in SPH2
Variable | Norepinephrine | Vasopressin | p |
|---|---|---|---|
Baseline characteristics norepinephrine- vs. vasopressin-treated patients prior to matching in SPH2 | |||
Age (years), X ± SD | 61.4 ± 16.8 | 60.9 ± 13.9 | 0.574 |
APACHE II, X ± SD | 21.1 ± 7.2 | 23.9 ± 6.4 | < 0.001 |
Gender (% male) | 66.4 | 62.4 | 0.617 |
Surgical (%) | 21 | 22.6 | 0.761 |
Renal (%) | 18.2 | 22.6 | 0.376 |
Hepatic (%) | 10.2 | 15.1 | 0.232 |
Neurological (%) | 36.5 | 32.3 | 0.48 |
Ventilated (%) | 82.7 | 82.8 | 0.985 |
Any chronic disease (%) | 45.3 | 50.5 | 0.401 |
Norepinephrine dose (ug/min) | 14.2 ± 13.6 | 19.2 ± 5.9 | < 0.001 |
Baseline characteristics norepinephrine- vs. vasopressin-treated patients after matching in SPH2 | |||
Age (years), X ± SD | 61.4 ± 14.5 | 60.9 ± 13.9 | 0.812 |
APACHE II, X ± SD | 23.8 ± 6.5 | 23.9 ± 6.4 | 0.939 |
Gender (% male) | 30.1 | 37.6 | 0.278 |
Surgical (%) | 19.3 | 22.6 | 0.589 |
Renal (%) | 20.4 | 22.6 | 0.721 |
Hepatic (%) | 15.1 | 15.1 | 1 |
Neurological (%) | 40.3 | 32.3 | 0.13 |
Ventilated (%) | 88.2 | 82.8 | 0.298 |
Any chronic disease (%) | 50.5 | 50.5 | 1 |
Norepinephrine dose (ug/min) | 16.9 ± 14.6 | 19.2 ± 15.9 | 0.242 |
Mortality of norepinephrine- vs. vasopressin-treated patients after matching in SPH2 | |||
28-day mortality (%) | 26.9 | 31.2 | 0.518 |